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Abstract
Background: For over 150 years, pathologists have relied on histomorphology to classify and
diagnose neoplasms. Their success has been stunning, permitting the accurate diagnosis of
thousands of different types of neoplasms using only a microscope and a trained eye. In the past
two decades, cancer genomics has challenged the supremacy of histomorphology by identifying
genetic alterations shared by morphologically diverse tumors and by finding genetic features that
distinguish subgroups of morphologically homogeneous tumors.
Discussion:  The Developmental Lineage Classification and Taxonomy of Neoplasms groups
neoplasms by their embryologic origin. The putative value of this classification is based on the
expectation that tumors of a common developmental lineage will share common metabolic
pathways and common responses to drugs that target these pathways. The purpose of this
manuscript is to show that grouping tumors according to their developmental lineage can reconcile
certain fundamental discrepancies resulting from morphologic and molecular approaches to
neoplasm classification.
In this study, six issues in tumor classification are described that exemplify the growing rift between
morphologic and molecular approaches to tumor classification: 1) the morphologic separation
between epithelial and non-epithelial tumors; 2) the grouping of tumors based on shared cellular
functions; 3) the distinction between germ cell tumors and pluripotent tumors of non-germ cell
origin; 4) the distinction between tumors that have lost their differentiation and tumors that arise
from uncommitted stem cells; 5) the molecular properties shared by morphologically disparate
tumors that have a common developmental lineage, and 6) the problem of re-classifying
morphologically identical but clinically distinct subsets of tumors. The discussion of these issues in
the context of describing different methods of tumor classification is intended to underscore the
clinical value of a robust tumor classification.
Summary: A classification of neoplasms should guide the rational design and selection of a new
generation of cancer medications targeted to metabolic pathways. Without a scientifically sound
neoplasm classification, biological measurements on individual tumor samples cannot be
generalized to class-related tumors, and constitutive properties common to a class of tumors
cannot be distinguished from uninformative data in complex and chaotic biological systems. This
paper discusses the importance of biological classification and examines several different
approaches to the specific problem of tumor classification.
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Background
Classifications provide a simplified view of a knowledge
domain, with members of the domain grouped in a class
hierarchy. Members of a class share one or more common
features and inherit the class features of their ancestral
classes [1,2]. Scientists use classifications to discover and
test generalizable methods and properties that may apply
to members of a class and their descendants. Much of the
following discussion relating to the purpose and proper-
ties of classifications was inspired by Ernst Mayr, one of
the leading evolutionary biologists of the past century [1].
Readers may have somewhat different views on the gen-
eral subject of classification, but the views presented here
are representative of a widely accepted approach devel-
oped by biologists.
The subject of tumor classification is made confusing by a
variety of commonly held notions about the meaning and
purposes of modern classifications [1]. Pathologists typi-
cally refer to anatomic tumor classifications when they are
more accurately referring to lists of primary tumors that
are known to occur at a particular location [3-7]. A list of
tumors occurring at a body site is not a classification
because it includes tumors that are biologically, clinically,
and histologically unrelated. Although often referred to as
World Health Organization (WHO) "classifications", the
WHO accurately titles their organ-based lists of neo-
plasms as "Histologic Typings" for the different organs [8-
12].
In the past decade, molecular biologists have tried to clas-
sify tumors based on grouping together tumor samples
that share similar gene expression profiles [13-16]. The
ability to separate tumors into groups is not equivalent to
separating tumors into classes because the groups may
represent expected variations of behavior within a single
tumor population. For example, tumor samples of a par-
ticular type of tumor may contain groups that are separa-
ble based on proliferation rate, cell death rate, size,
invasiveness, dominance of glycolytic enzyme pathways,
etc. Variant groups within a population do not qualify as
classes if it can be shown that the differences between the
groups can be accounted for by transient differences in a
tumor's biology. If a slow-growing tumor becomes a fast-
growing tumor over time, or if a single tumor has foci of
slow growth and fast growth, then the tumor cannot be
classed by its rate of growth. A key principle in classifica-
tion is that classes are intransitive (i.e. instances of a class
never change their classs) [1]. Carcinomas never become
lymphomas and lymphomas never become carcinomas.
Grouping tumors by shared gene expression profiles may
indicate that a certain tumor shares a similar profile with
another tumor (for a chosen set of expressed genes), but it
does not guarantee an intransitive classification of
neoplasms.
2004 marked the introduction of a classification of
tumors based on developmental lineage [2] similar to that
proposed by pathologists in the mid-20th century [17].
The rationale for the new classification is that tumor cells
will tend to use metabolic pathways inherited from their
ancestral cells within their developmental lineage [see:
Figure 1]. As pathway-specific targets for cancer treatment
become available for clinical trials, it may prove effica-
cious to test these agents on tumors that have a common
lineage [18]. Also in 2004, a comprehensive taxonomy of
neoplasms was created by expanding the NCI-Thesaurus
[19-21]. The new taxonomy contains over 140,000 names
of neoplasms and is included as a supplemental file with
this manuscript [see Additional file 1]. This taxonomy was
ported into the new classification of neoplasms to create
"The developmental lineage classification and taxonomy
of neoplasms," hereinafter called "The developmental
classification"[19].
In addition to providing a useful nomenclature for neo-
plasms, the taxonomy reconciles differences between
morphology-based classifications of neoplasms (favored
by pathologists) and newly emerging classifications based
on genomic characterizations of tumors [22-24]. Specific
features of the developmental classification and taxon-
omy are [2]:
1. The classification is comprehensive (e.g. every tumor of
man can be placed somewhere within the classification,
which is the largest listing of neoplasm terms [19]. It is
available at no cost in XML and flat-file formats. In either
format, each term is annotated with its complete ancestral
lineage. The most recent version of the nomenclature is
made available at the Association for Pathology Informat-
ics download page [25].
2. The classification is simple. One of the purposes of a
classification is to drive down the complexity that exists
when the domain taxonomy is large. The entire classifica-
tion is described by under 40 classifiers.
3. The classification is based on biologic principle and is
not determined by an artificial construct such as medical
specialty (e.g. dermatologic neoplasms) or by anatomi-
cally vague regions (e.g. head and neck tumors) or by any
single taxon (e.g. epithelial versus spindled morphology)
4. The classification is represented as an eXtensible
Markup Language (XML) document that permits data
integration between heterogeneous biomedical databases.
5. The classification does not invalidate existing diagnoses
found in pathology reports. The medicolegal importance
of this feature cannot be exaggerated. This relieves
pathologists from reviewing all their prior cases and re-BMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
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diagnosing them in conformance with a new
classification.
The developmental classification is not based on morpho-
logic or genomic properties of tumors. It is based on
developmental lineage. However, the class instances (i.e.,
tumors) all have morphologic and genetic properties.
Genetic changes that control particular pathways leading
to a particular morphologic phenotype may have class
specificity within the developmental classification [26].
Consequently, the developmental classification can be
examined to determine how it deals with apparent dis-
crepancies between the morphologic and molecular clas-
sifications of neoplasms.
In this study, six fundamental issues in tumor classifica-
tion are described that exemplify the growing rift between
morphologic and molecular approaches to tumor classifi-
cation: 1) the separation between epithelial and non-epi-
thelial tumors; 2) the grouping of tumors based on shared
cellular functions; 3) the distinction between germ cell
tumors and pluripotent tumors of non-germ cell origin;
4) the distinction between tumors that have lost their dif-
ferentiation and tumors that arise from uncommitted
stem cells; 5) the molecular properties shared by morpho-
logically disparate tumors that have a common develop-
mental lineage, and 6) the problem of re-classifying
morphologically identical but clinically distinct subsets of
tumors. The discussion of these issues in the context of
describing different methods of tumor classification is
intended to underscore the clinical value of a robust
tumor classification.
The purpose of this manuscript is to show that grouping
tumors according to their developmental lineage can rec-
oncile certain fundamental discrepancies resulting from
morphologic and molecular approaches to neoplasm
classification.
Discussion
The separation between epithelial and non-epithelial 
tumors
The separation of tumors into two large groups, epithelial
and non-epithelial, is a popular device [27-31]. It has cer-
tain practical advantages for clinicians. If a patient has a
brain mass that is stereotactically biopsied, the patholo-
gist can make a quick, intra-operative consultation based
on a small sampling of the specimen, reporting that the
tumor is epithelial or non-epithelial. If it's epithelial, the
tumor is unlikely to be a primary brain tumor. It is much
more likely to be a metastatic lesion from a primary carci-
noma that arose somewhere else in the body. The treat-
ment of a primary brain tumor is different from the
treatment of a metastatic tumor to the brain. Hence, the
intra-operative assessment of epithelial morphology can
be very helpful to the surgeon.
Developmental Lineage Classification Schema [2] Figure 1
Developmental Lineage Classification Schema [2].BMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
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Despite the clinical utility, the separation of tumors into
epithelial and non-epithelial subtypes does not provide a
consistent dichotomy for tumor classification. Experts in
the field of classification consider it poor form to create a
class based on criteria of exclusion. Classifications are
intended to identify properties common to classes [1].
There is seldom much value in assigning class member-
ship based on the absence of a property found in another
class.
In the specific case of a morphologic separation of tumors
into epithelial and non-epithelial classes, a problem arises
when experts do not agree on the qualifications of epithe-
lial tumors. Some might argue that epithelial tumors are
tumors that arise from an epithelium (e.g., squamous cell
carcinoma) or an epithelial glandular lining (e.g., adeno-
carcinoma). The qualifying features of an epithelium are
controversial. Are mesothelial cells (which cover the sero-
sal surfaces of the pleura and peritoneum) epithelial cells?
Mesotheliomas arising from coelomic epithelium are
classed as [non-epithelial] sarcomas. Are specialized mes-
othelial cells that cover the serosal surface of the ovaries
epithelial? Ovarian tumors arising from specialized coe-
lomic mesothelium, including papillary cystadenocarci-
noma, are classed as epithelial tumors.
Some pathologists divide tumors into epithelial and non-
epithelial classes based purely on morphology without
regard to their tissues of origin. An epithelial cell is a
round or polyhedral cell that adheres closely to other
tumor cells with desmosomes (cell junctions). Patholo-
gists subscribing to a purely morphologic separation of
tumors face an assortment of problems when they try to
maintain a dichotomous classification.
1. Some tumors are mixed epithelial and non-epithelial
(mixed tumor of salivary gland, fibroadenoma of breast,
synovial sarcoma, carcinosarcoma of uterus) [29,32].
2. Some tumors that are typically epithelial can have non-
epithelial variants (e.g., sarcomatoid squamous cell carci-
noma, spindle cell nevus, sarcomatoid melanoma).
3. Some tumors that are typically non-epithelial can have
epithelial morphology (epithelioid leiomyoma) or mor-
phologic features in common with epithelial tumors
(clear cell sarcoma of soft parts) [33]
4. Biochemical markers intended to distinguish epithelial
fron non-epithelial cells often co-express in epithelial and
non-epithelial tumors [30].
Aside from the failure of the epithelial/non-epithelial
dichotomy to provide a consistent basis for tumor classi-
fication, this approach to tumor classification creates dis-
crepancies with molecular classifications of tumors.
Genetic markers characteristic of tumors can occur in both
epithelial and non-epithelial cancers. Furthermore, a sin-
gle oncogene or molecular marker may characterize both
epithelial and non-epithelial tumors [15,34,35]. This
means that the epithelial/non-epithelial tumor dichot-
omy conflicts with a molecular classification of tumors.
The developmental classification assigns morphologically
diverse tumors to a single class if they have the same
developmental lineage. Morphologic attributes (such as
epithelial or non-epithelial appearance) can be preserved
as tumor annotations.
Classifying tumors based on shared cellular functions
The endocrine tumors exemplify the confusion that
occurs when tumors are classified by common function.
Examples of endocrine organs include the thyroid gland
and the adrenal gland. The U.S. National Cancer Institute
lists 8 major endocrine glands and several other tissues
that secrete physiologically active hormones [36].
Pituitary gland
Pineal gland
Thyroid gland
Parathyroid gland
Adrenal gland
Pancreatic islets of langerhans
Gonads (testes and ovaries)
Other endocrine glands – thymus, stomach, small intes-
tines, heart, and placenta.
The problem with considering the endocrine tumors as a
single class of tumors is that other than a common func-
tion (i.e. hormone secretion), tissues of the endocrine sys-
tem my have nothing in common morphologically,
genetically, or developmentally. Some of the endocrine
glands have epithelial morphology (e.g. thyroid) others
have spindle morphology (e.g. ovarian stroma). Any sin-
gle endocrine gland is likely to contain several specialized
cell types. The pituitary gland is divided into adenohypo-
physis (glandular part of the pituitary) and neurohypoph-
ysis (neural part of pituitary). The thyroid contains
follicular cells and small nests of so-called C-cells that
produce calcitonin. Thyroid follicular cells have an endo-
dermal origin and thyroid C-cells have a neural crest ori-
gin. The adrenal gland has an epithelial cortex and a
morphologically distinctive medullary portion. TheBMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
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adrenal cortex derives from mesoderm. The adrenal
medulla consists of paraganglia cells derived from neural
crest. As judged by embryologic origin and by morphol-
ogy, the endocrine glands have no common [class]
properties.
Within any endocrine organ are a variety of specialized
cells that give rise to morphologically and clinically
diverse neoplasms. The following list of tumors comprises
a published "Classification of thyroid neoplasms" [37].
Follicular adenoma
Papillary adenoma
Atypical adenoma
Papillary carcinoma
Follicular carcinoma
Undifferentiated anaplastic carcinoma
Medullary carcinoma
Squamous cell carcinoma
Metastatic carcinoma
Fibrosarcoma
Angiosarcoma
Lymphoma
Teratoma
Other sarcomas
(oxyphil and clear cell variants listed as variants, not as
members of the primary classification)
This classification of thyroid neoplasia includes tumors
from several different lineages, including endodermal
(e.g., follicular carcinomas of thyroid), neural crest (e.g.
medullary carcinoma) mesenchymal (e.g., fibrosarcoma)
and germ cell (e.g., teratoma). It seems unlikely that a sin-
gle carcinogenic process would be responsible for the
diverse tumors occurring in the thyroid or that a single
metabolic pathway would provide a rational treatment
target for all these tumors.
The advantages of classing endocrine neoplasms by line-
age, rather than by function, become apparent when
examining the co-occurrence of endocrine neoplasias in
inherited tumor syndromes. Inherited tumor syndromes
have germline aberrations that lead to multiple types of
tumors occurring in affected individuals [38]. In many
cases, the specific germline mutation or the involved met-
abolic pathway of an inherited syndrome has been char-
acterized. Inherited disorders often involve tissues derived
from a single developmental lineage (the "One disorder –
One developmental lineage" rule). The following three
generalizations demonstrate the concept:
1. Tumor syndromes that involve endocrine tumors and
non-endocrine tumors recruit both endocrine tumors and
non-endocrine tumors from a single developmental
lineage
Example:
MEN2B – OMIM # 162300 (neural crest)
A single identical point mutation (exon 16) in the cata-
lytic core of the tyrosine kinase domain of the ret gene has
been found to be associated with both inherited and de
novo MEN2B
Ganglioneuroma (ganglioneuromatosis);
Pheochromocytoma;
Calcitonin secreting medullary thyroid carcinoma;
*Parathyroid hyperplasia/adenoma (probably secondary
to calcitonin secretion)
2. Tumor syndromes that exclusively involve endocrine
tumors tend to recruit tumors from a single developmen-
tal lineage
Example:
MEN1 – OMIM # 131100 (endodermal origin)
The MEN1 gene contains 10 exons and encodes a ubiqui-
tously expressed 2.8-kb transcript. The predicted 610-
amino acid protein product is termed menin, a putative
tumor suppressor protein inactivated by MEN1
mutations.
Pancreatic islet cell adenoma;
Parathyroid adenoma;
Pituitary adenoma;
ProlactinomaBMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
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Glucagonoma
Insulinoma
Vasointestinal peptide tumor
Gastrinoma
Carcinoid tumors
*Adrenocortical adenoma (secondary to Cushing syn-
drome [39])
3. Tumor syndromes associated with a mutation of a sin-
gle metabolic pathway tend to recruit endocrine and non-
endocrine tumors from a single developmental lineage.
Example:
Complex II mitochondrial pathway-associated tumors
(neural crest [40])
Complex II, of which succinate dehydrogenase (EC
1.3.99.1) is a component, has 4 subunits:
The flavoprotein (SDHA; 600857),
No tumors, but is associated with Leigh syndrome of
infantile subacute necrotizing encephalopathy [OMIM
record 256000]
The iron sulfur protein (SDHB; 185470)
Carotid body tumors (cervical paraganglioma), and mul-
tiple extra-adrenal pheochromocytomas [41,42] [OMIM
record 115310]
Pheochromocytoma [OMIM record 171300]
The 2 integral membrane proteins
SDHC (602413)
Familial nonchromaffin paragangliomas type 3 [OMIM
recrod 605373][43]
SDHD (602690)
Paragangliomas, chemodectomas, carotid body tumors,
glomus jugulare tumors [OMIM 168000]
Exceptions occur, and this is to be expected considering
the multi-factor and multi-step nature of carcinogenesis.
Tumors occurring in the von Hippel-Lindau syndrome
(VHL) pose a seeming exception to the "One disorder –
One lineage" rule. VHL is is a dominantly inherited famil-
ial cancer syndrome predisposing to a variety of malig-
nant and benign neoplasms, most frequently retinal,
cerebellar, and spinal hemangioblastoma, renal cell carci-
noma, pheochromocytoma, and pancreatic endocrine
tumors. It is caused by mutation in the VHL gene [OMIM
record 608537]. VHL is characterized by tumors of the
mesenchyme consisting of unusual angiomata, including
angioma of retina and spinal cord, and hemangioblast-
oma of cerebellum. Also seen are pheochromocytomas
(neural crest), renal cell carcinomas (mesoderm), and
pancreatic islet cell tumors (endoderm). There are several
possible explanations for this multilineage tumor syn-
drome. The mutation may involve a general cancer gene
that triggers carcinogenic events independent of cell line-
age. Alternately, VHL may be a complex disease that can
involve multiple mutations targeting different develop-
mental lineages. There is a tendency for specific combina-
tions of tumors to cluster in different VHL families [44].
Both angiomatosis retinae and hemangioblastoma of the
CNS occurred in most families, while renal cancer did not
occur in VHL families with pheochromocytoma. This may
mean that VHL is not a single mutational disorder. Per-
haps the simplest hypothesis is that the VHL mutation tar-
gets [for carcinogenic transformation] a stem cell that
precedes differentiation of the embryonic layers (endo-
derm, ectoderm, mesoderm and neuroectoderm). The
tumors that occur in VHL families may therefore arise
from any of the lineages that descend from the [hypothet-
ical] VHL cancer stem cell.
A molecular classification of neoplasms tied to function
(e.g., endocrine function) does not serve as a consistent
class scaffold. Germline mutations that predispose to can-
cer do not select for target tissues that share a common
function. Selection seems to favor tissues that share a
common developmental lineage.
The distinction between germ cell tumors and pluripotent 
tumors of non-germ cell origin
Nowhere is the dissonance between morphology, molec-
ular biology and developmental biology more striking
than in the realm of the germ cell tumors. The germ cell
tumors include tumors of diverse morphology, including
seminomas (male), dysgerminomas (female), teratomas,
embryonal carcinomas, endodermal sinus tumors, and
some (but not all!) cases of choriocarcinoma [45]. Germ
cell tumors also have diverse molecular markers with
cytogenetic changes correllating with age of patient rather
than type of germ cell tumor. Pediatric germ cell tumors
show imbalances in of chromosome 1 and loss of 6q,
while adult germ cell tumors often have an isochromo-
some 12p or amplification of 12p [45]. Germ cell tumors
arise in almost any part of the body (particularly midline
locations) and any age (with a pediatric dominance). ItBMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
Page 7 of 12
(page number not for citation purposes)
was difficult to imagine a way of placing all these tumors
into a single class of neoplasms until Teilum suggested
that all these tumors had the same cell of origin, the pri-
mordial germ cell [46]. The biologic mechanism by which
one cellular progenitor can give rise to these seemingly
unrelated tumors is still unfolding as a fascinating saga of
developmental biology [45].
Germ cells normally follow a narrow developmental path.
Male germ cells give rise to spermatocytes. Female germ
cells give rise to oocytes. Under normal circumstances,
germ cells are not pluripotent and are not related to
embryonic stem cells. The only tumors arising directly
from neoplastic germ cells are pure seminomas and dys-
germinomas (the female equivalent of seminomas). At an
early embryonic stage, primordial germ cells undergo a
complete erasure of epigenetic programming, a phenom-
enon that uniquely characterizes these cells. This phe-
nomenon precedes the transformation of primordial
germ cells into embryonic stem cells in culture, is the
putative mechanism that operates in animals to provide
neoplastic precursors of totipotent tumors, and provides a
biological rationale for separating germ cell tumors from
other embryonic tumors [47-49]. It permits us to think of
germ cells and their normal descendants (ova and sperm)
as tumors occupying their own sub-class. We can think of
the totipotent and embryonic tumors as tumors of embry-
onic stem cells (not germ cells). These embryonic stem
cells may have derived from the phase of germ cell devel-
opment when epigenetic programming is erased [48,49],
but the resulting cells can be separately classified based on
their biology and their shared epigenetic properties char-
acteristic of a totipotent phenotype. By separating tumors
of embryonic cells from tumors derived from germ cells,
certain incongruities are avoided. In the developmental
classification, a gestational choriocarcinoma (arising from
cytotrophoblasts and syncytiotrophoblasts in the placenta
and having no derivation from germ cells) can now be
classed separately from seminomas. Furthermore, new
drugs that target the germ cell tumors may find that differ-
ences in the genomic state of germ cell tumors and embry-
onic tumors (i.e., methylation patterns) may uncover
vulnerabilities that provide new treatment options.
Finally, a developmental classification that distinguishes
germ cell tumors and embryonic tumors reconciles the
fundamental differences between the morphologic and
cytogenetic incongruities among these unique tumors.
The distinction between tumors that have lost their 
differentiation and tumors that arise from embryonic stem 
cells
Tumors that have grown into large tumor masses that
deeply invade surrounding tissues and metastasize to
many distant organs tend to have different morphology
than tumors that are small and pre-invasive. Tumors in so-
called late lesions tend to acquire morphologic features
that are not found in non-neoplastic cells. The nucleus is
markedly different from the normal nucleus with angula-
tions of the nuclear membrane, splotchy chromaticity
within the nucleus, and marked variation in nuclear size
and shape from one tumor cell to the next. Cellularity is
often high (i.e. more cells in a microscopic field compared
with normal tissues). Mitotic figures, which may be abun-
dant in a late tumor, tend to have abnormal mitotic spin-
dles. Cytogenetics performed on late tumors often show
aneuploidy with multiple, complex karyotypic abnormal-
ities. In general, late lesions of widely different tumor
types often resemble one another more than they may
resemble the early cancer from which they arose. Patholo-
gists often refer to tumors that have lost differentiated
morphologic features [found in early lesions] as undiffer-
entiated or poorly differentiated malignancies, implying
that the tumor cells have lost properties characteristic of
differentiated cell lineages.
A number of tumors, particularly in childhood, consist of
cells that have no apparent developmental cell lineage.
The small round cell tumors of childhood are prototypical
examples. These tumor cells tend to have a uniform size
within the tumor. They tend to be characterized by very
specific balanced translocations leading to the creation of
specific fusion genes [50]. These tumors are sometimes
referred to as undifferentiated or primitive neoplasms.
The pathologist's concept of an "undifferentiated" tumor
has been applied to such biologically diverse tumors as
Ewing's tumor and late stage colon carcinomas. This
exemplifies the limitations of grouping tumors using a
morphologic feature (such as loss of differentiation) that
does not distinquish pathogenetic mechanisms. By classi-
fying tumors by their developmental lineage, useful mor-
phologic features (including extent of differentation) can
be applied without obscuring the class features that define
the different tumor types.
The relationship among morphologically disparate tumors 
that share a developmental lineage
Epithelial tumors of the kidney and of the uterus have bio-
logic features that separate them from epithelial tumors in
other organs. Furthermore, many of the properties of epi-
thelial tumors arising from kidney or from uterus are spe-
cifically associated with mesenchymal tumors.
The gene expression profiles of renal epithelial tumors are
much more closely related to the gene expression profiles
of sarcomas than of epithelial tumors derived from other
organs [15]. Several epithelial tumor variants are charac-
terized by specific tranlocations resulting in fusion genes
[34,35,51]. Fusion genes are much more characteristic of
sarcomas than epithelial tumors [24]. MesoblasticBMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
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nephroma, shares an identical fusion marker (TV6-
NTRK3) with congenital fibrosarcoma [52]. Several vari-
ants of renal epithelial tumors have the same gene fusion
marker as alveolar soft part sarcoma [34,35]. A diverse
array of epithelial, stromal and mixed epithelial-stromal
tumors are known to arise from kidney parenchyma [53].
How is it possible for an epithelial organ to give rise to
epithelial and stromal tumors with epithelial tumors char-
acterized by sarcoma molecular markers?
The kidney is an epithelial organ that has mesodermal lin-
eage. No cells in the kidney arise from endoderm or ecto-
derm, the major embryonic lineages that give rise to most
epithelial tumors. In a sense, the kidney is a stromal organ
that masquerades as an epithelial organ. The only way to
reconcile the discrepancy between morphologically epi-
thelial renal tumors and their sarcomatous molecular fea-
tures is to recognize that renal tumors can be classed
according to their mesodermal lineage [2].
A similar story holds for uterine tumors. The uterus gives
rise to adenocarcinomas, sarcomas, and variously named
mixed tumors including carcinosarcomas, adenosarco-
mas, and mixed mullerian tumors with heterologous
components. The histogenesis of mixed epithelial and
stromal tumors of the uterus has always presented a spe-
cial intellectual challenge. Both epithelial and non-epithe-
lial tumors of the uterus seem to have an association with
tamoxifen therapy [54], suggesting the possibility that a
single stem cell targeted by tamoxifen can give rise epithe-
lial and stromal tumors of the uterus.
In most other organs, epithelial cells do not share their
genesis with mesenchymal cells. But the uterus, like the
kidney, is derived entirely from mesoderm. The uterus is
formed from a duct that forms within the mesoderm (the
paramesonephric duct). This duct gives rise to the
endometrial epithelium as well as the underlying stroma.
Consequently, tumors of endometrial and stromal cells
share the same lineage in the developmental classification
(sub-coelomic ductal). Like the kidney, this classification
ignores morphologic differences (epithelial versus mesen-
chymal) and creates a grouping in concordance with the
observed mixed epithelial/stromal manifestations of
some uterine tumors. This is another example wherein the
developmental classification accommodates morphologic
class ambiguity.
The problem of determining when morphologically 
identical but clinically distinct subsets of tumors constitute 
new slots in the classification
Whenever new subpopulations of tumors can be deline-
ated, the question of classification arises. If a report shows
that a fraction of a certain type of tumor has a special mor-
phologic feature, does the morphologic variant qualify as
a new subclass of the tumor? If a tumor can be divided
into two distinct clusters based on gene expression pro-
files, is each cluster a new subclass of the tumor? If
patients with a certain tumor can be divided into good
prognosis and bad prognosis groups, can the tumor be
subclassified based on clinical prognosis? The problem
with classifying based on morphologic, molecular or clin-
ical features is that any population can be expected to con-
tain members with features that vary from the population
norm. There is a difference between segregating popula-
tion variants (e.g. fast runners and slow runners, choco-
late lovers and chocolate haters) and creating a self-
consistent classification. A classification has certain prop-
erties that distinguish it from other ways of organizing
data. The general rules for classifications have been sum-
marized [1,2]:
1. A classification is a hierarchical grouping, with each
group defined by the greatest number of taxa (informative
features) that can apply to every instance of the class.
2. Subclasses inherit the properties (shared taxons) of
their ancestor classes.
3. Every instance of the knowledge domain must fit into
the classification, and every instance and class must have
exactly one slot in the classification.
4. Instances of one class are intransitive (e.g. an instance
in one class cannot migrate to a different class, but must
remain in the same class or a subclass of the same class).
5. A classification is a hypothesis about the fundamental
properties of a knowledge domain. The hypotheses must
be tested and re-tested and changed when the facts do not
fit the model.
If a tumor lacks a morphologic or molecular feature at one
point in its development and gains the feature at a later
point, the feature cannot determine a new class of tumor.
If a tumor has a good prognosis at one point (e.g. before
it has metastasized) and a bad prognosis later (e.g. after it
has metastasized), then prognostic features associated
with metastasis cannot be used to determine a new class
of tumor. In general, all new findings about subpopula-
tions of tumors can be considered candidate taxa (i.e., fea-
tures that characterize a class and distinguish the class
from other classes). The full list of class features (items 1–
5 above) must be satisfied before a candidate taxon can be
used to define a new tumor class.
The future role of morphology and molecular analysis in 
tumor classification
Morphologic pathology has dominated tumor diagnosis
for over 150 years [55]. The demise of morphologicBMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
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pathology is a long-anticipated event that may never
occur. In fact, the morphologic pathologist is a key devel-
oper of emerging technologies that promise the end of our
dependence on histologic evaluation of lesions. It is the
pathologist who prepares, describes and diagnoses the tis-
sue samples used by the molecular biologist. It is the
pathologist who collects, organizes and integrates the
information in the patient's surgical pathology report
with demographic information (age, gender), medical
history, tumor staging, and ancillary hospital tests (radiol-
ogy reports, hematology reports, and past/future tissue
reports). In most cases, researchers would have no tumor
samples for gene expression profiling if the pathologists
had not been able to distinguish the tumor samples by
careful morphologic evaluation. In all cases, the clinico-
pathologic annotations used by the molecular biologist
are generated in whole or in part by surgical pathologists.
It has been noted that, "the pathologist's understanding of
anatomic, physiologic, biochemical, immune, and other
underlying factors that drive mechanisms of tissue
responses to noxious agents turns a bewildering array of
gene expression data into focused research
programs"[56].
If molecular classification is to replace the morphologic
classification of tumors, several seemingly intractable
problems must be solved. Cytogenetic abnormalities and
gene alterations in tumors co-occur with other abnormal-
ities, and the complex state of molecular abnormalities in
tumors makes it very difficult to settle on a set of altera-
tions characteristic of classes of tumors. As an example,
balanced translocations play biologic roles in several
dozen tumors [24]. Although certain translocations are
characteristic of individual tumors, it has proven difficult
to generalize that translocations occur in any particular
class of tumors. Certainly, characteristic tumor transloca-
tions occur more commonly in mesenchymal tumors
[24], but such translocations have also been observed in
secretory carcinoma of breast [57] and in midline [lung]
carcinoma of children and young adults [58]. The notable
exception wherein a class of tumors is characterized by a
set of translocations is the Ewing's tumor family of tumors
[50].
Mitelman has argued that translocations are tissue non-
specific, occurring at a frequency related to the overall
number of cytogenetic abnormalities found in tumors
[59]. If it is difficult to assign classes of tumor to a single
type of cytogenetic abnormality, it may be impossible to
reach scientific consensus on complex sets of molecular
signatures that define groups of tumors. It can be noted
that despite numerous projects aimed at classifying
tumors with gene expression profiles, no comprehensive
classification based on this technology has emerged.
Much of what passes for neoplasm "classification" in the
bioinformatics literature is actually the algorithmic rank-
ing of expressed genes that can discriminate one tumor
variant from another [13,14,60]. Once candidate mole-
cules (i.e., genes, proteins, and other macromolecules or
patterns of these molecules) are found to associate with a
particular tumor variant, the pathologist gets a second
chance to determine if a morphologic pattern correlates
with the molecular property. An example comes from the
study of gastrointestinal stromal tumors (GIST). Most
GIST tumors have a c-Kit mutation that results in c-Kit
protein overexpression [61]. Some GIST tumors lacking c-
Kit mutations have a mutation in the platelet-derived
growth factor receptor alpha gene [62]. Sakurai and cow-
orkers have examined GIST tumors that stain negatively
for CD-117, a marker for c-Kit protein overexpression.
Many of these tumors have mutations in platelet-derived
growth factor receptor alpha gene and a distinctive histo-
morphology characterized by myxoid epithelioid tumor
cells and tumor infiltration by mast cells [63]. This newly
recognized subtype of GIST involved the morphologic re-
examination of the tumors following a molecular
discovery.
Other examples abound. Secretory carcinoma of breast is
an uncommon variant of breast cancer that occurs most
frequently in young women. It is characterized by the
ETV6-NTRK3 fusion gene [57]. The search and discovery
of this molecular marker was accomplished through asyn-
chronous contributions from three biomedical realms: 1)
pathologists, who found defined the morphologic subset
of breast carcinoma known as secretory carcinoma of
breast; 2) oncologists who validated the clinically distinct
features of the tumor, and 3) molecular biologists who
discovered the translocation that characterized the tumor.
It is a basic assumption of the developmental classifica-
tion that morphologic and molecular features of tumors
will both fall sensibly into classes determined by tumor
cell lineage. It is further assumed that pathways with
molecular alterations producing a tumor phenotype will
tend to operate in all tumors of a developmental class.
Finally, it is hoped that morphologic properties associated
with the altered pathway will be visible in all class mem-
bers. Because classifications are hypotheses about the fun-
damental nature of a knowledge domain, the
foundational assumptions of any classification must be
continually evaluated and challenged.
Some classifications can be challenged more easily than
others. A classification built on a set of continually chang-
ing parameters is constantly changing and difficult to
evaluate. This is certainly true of a molecular classifica-
tion, because our knowledge of the field changes almost
daily. A few years ago, it was safe to say that all recurrentBMC Cancer 2005, 5:100 http://www.biomedcentral.com/1471-2407/5/100
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balanced translocations were a phenomenon of mesen-
chymal tumors. New findings of recurrent balanced trans-
locations in non-mesenchymal tumors have nullified this
class assertion [59]. Morphologists once classified clear
cell sarcoma as a type of malignant melanoma, based on
finding melanosomes within tumor cells. Recent molecu-
lar classification of these tumors clearly distinguish them
from cutaneous melanoma. Clear cell sarcomas have char-
acteristic EWS-AFT1 fusion transcript not found in cutane-
ous melanomas [64]. In addition, BRAF mutations,
commonly found in cutaneous melanomas, are absent
from clear cell sarcomas [65]. The rapid accumulation of
new knowledge about the molecular characteristics of
tumors can quickly change classifications built on mor-
phology or molecular biology. Pathologists seem to be
putting this tumor back into the mesenchymal class of
neoplasms [66].
The developmental classification is built on a foundation
of developmental biology that was improved over many
decades by thousands of scientists. Our understanding of
embryologic lineage has changed very little over the past
half century, and a classification based on developmental
biology permits tumors to be assigned to well-defined
classes. Recent advances in embryology have shown that
somatic DNA has lineage-specific epigentic modifications
that occur throughout development [47,67]. This means
that the developmental lineage of tumors may be measur-
able and refinable with new techniques that correlate pat-
terns of epigenetic modifications (e.g. methylation) with
lineage. In a recent paper by Kho and coworkers [68], the
authors developed a method that projects gene expression
profiles of tumors onto a mouse developmental sequence.
Human medulloblastoma most closely matched the gene
expression profile of postnatal day 5 mouse cerebellum.
Although this study examined only a few tumors, it
described a method that allows any human tumor to be
matched against a library of gene expression profiles col-
lected from normal tissues at different stages of
development.
Summary
A scientifically sound classification of neoplasms will
serve as a guide to selecting a new generation of cancer
medications targeted to metabolic pathways specific for
particular classes of tumors. Without a classification of
tumors, biological measurements on individual tumor
samples cannot be generalized to other tumors, and con-
stitutive properties common to a class of tumors cannot
be distinguished from uninformative data collected from
a complex and chaotic biological system. Morphology,
even in the post-genomic era, has enormous value in the
realm of taxon discovery. Using morphologic examina-
tion, pathologists have discovered previously unrecog-
nized morphologic features that are diagnostic for new
tumors or new clinical variants of known tumors that
have characteristic molecular profiles. By classifying
tumors by lineage, problems arising from molecular and
morphologic tumor classifications can be resolved or
posed as testable hypotheses.
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